Her-2/neu Gene Amplification and Protein Expression in Primary Male Breast Cancer

AbstractTreatment principles of breast cancer in males are derived from studies performed among females, while the low incidence in males has so far precluded such studies. The therapy recommendations for males therefore lack the solid evidence, frequently present for females with breast cancer. The primary breast cancer diagnosis in males is not infrequently in stage III/IV and at higher age, thereby requiring multiprofessional and multimodal management including preoperative therapy and adjuvant therapies based on the tumour’s biological characteristics and the clinical circumstances. The majority of male breast cancer tumours are oestrogen-receptor positive and adjuvant/neoadjuvant tamoxifen is therefore recommended, surgery is frequently radical mastectomy and adjuvant radiotherapy should likely be used on wider indications. Chemotherapy should be considered both in the adjuvant and metastatic setting for receptor-negative cancers and for patients with biologically aggressive disease. Trastuzumab should be offered to patients with Her-2/neu-positive disease, while the use of aromatase inhibitors is more uncertain due to differences in the hormonal environment in males.

Download Full-text

Unusual Male Breast Lesions

Journal of Clinical Imaging Science ◽

10.25259/jcis_43_2021 ◽

2021 ◽

Vol 11 ◽

pp. 21

Author(s):

Shaza AlSharif ◽

Khalid Misfer Alshamrani ◽

Anabel Scaranelo ◽

Nuha Khoumais ◽

Ahmad Subahi ◽

...

Keyword(s):

Breast Cancer ◽

Male Breast Cancer ◽

Diagnostic Algorithm ◽

Breast Tumors ◽

Male Breast ◽

Breast Lesions ◽

Imaging Features ◽

Breast Masses ◽

Female Breast ◽

Primary Male

Most of male breast masses are benign with gynecomastia being the most common entity encountered. Primary male breast cancer accounts for less than 1% of the total number of breast cancer. Male breast can be affected by a variety of conditions affecting the female breast with less frequency due to the lack of hormonal influence and consequent glandular sub-development. Imaging features of male breast masses are quite similar to the female breast. Therefore, using the knowledge of the female breast and applying it may help in the diagnosis and management of male breast abnormalities. In this article, we aim to review a variety of unusual male breast masses. We discuss the demographics of male breast tumors, describe the diagnostic algorithm for evaluating male breast masses, and review the imaging features of rare breast masses and mimickers of male breast cancer.

Download Full-text

Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer

Scientific Reports ◽

10.1038/s41598-021-04342-0 ◽

2022 ◽

Vol 12 (1) ◽

Author(s):

Nan Yao ◽

Wenzai Shi ◽

Tong Liu ◽

Sarah Tan Siyin ◽

Weiqi Wang ◽

...

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Competing Risks ◽

Male Breast Cancer ◽

Cox Regression ◽

Female Breast Cancer ◽

Male Breast ◽

Limited Information ◽

Female Breast ◽

Her 2

AbstractMale breast cancer (MBC) is rare. Due to limited information, MBC has always been understudied. We conducted a retrospective population-based cohort study using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program. The clinical and biological features of female breast cancer (FBC) patients were compared with MBC patients. Cox regression models and competing risks analyses were used to identify risk factors associated with cancer-related survival in MBC and FBC groups. Results showed that MBC patients suffered from higher TNM stages, tumor grades, and a higher percentage of hormone receptor-positive tumors, compared with FBC patients (all p < 0.05). In addition, the breast tumor locations varied a lot between males and females (p < 0.05). FBC patients were associated with superior overall survival than MBC patients. Results from multivariate cox regression and competing risks analyses showed age, race, T, N, M-stages, tumor grades, estrogen receptor (ER)/progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2) overexpression were independent prognosis factors in FBC patients (all p < 0.05). MBC patients had similar risk factors to FBC patients, but PR and HER-2 status did not independently influence survival (all p > 0.05). Tumor location was an independent prognostic factor for both gender groups.

Download Full-text